DoH Policies screened during the period 1 July 2022 – 30 September
Date published:
In fulfilling its obligations under Section 75 the Department is required to equality screen all of its policies and services under consideration to determine whether they should be subject to a full equality impact.
Documents
- NICE Technology Appraisal TA794 - Diroximel fumarate for treating relapsing–remitting multiple sclerosis. (PDF 512KB)
- NICE Technology Appraisal TA795 - Ibrutinib for treating Waldenstrom’s macroglobulinaemia (review of TA491) (PDF 513KB)
- NICE Clinical Guideline NG215 - Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults (PDF 630KB)
- NICE Technology Appraisal TA798 - Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation (review of TA578) (PDF 513KB)
- NICE Technology Appraisal TA796 - Venetoclax for treating chronic lymphocytic leukaemia (review of TA487) (PDF 512KB)
- NICE Technology Appraisal TA801 - Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer (PDF 624KB)
- NICE Technology Appraisal TA802 - Cemiplimab for treating advanced cutaneous squamous cell carcinoma (review of TA592). (PDF 512KB)
- NICE Technology Appraisal TA804 - Teduglutide for treating short bowel syndrome. (PDF 510KB)
- NICE Technology Appraisal TA808 - Fenfluramine for treating seizures associated with Dravet syndrome (PDF 512KB)
- NICE Clinical Guideline NG219 - Gout: diagnosis and management (updates and replaces TA164) (PDF 512KB)
- NICE Technology Appraisal TA803 - Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs (PDF 514KB)
- NICE Technology Appraisal TA810 - Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence. (PDF 558KB)
- NICE Technology Appraisal TA807 - Roxadustat for treating symptomatic anaemia in chronic kidney disease (PDF 511KB)
- NICE Technology Appraisal TA805 - Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides. (PDF 557KB)
- NICE Technology Appraisal TA812 - Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer (PDF 510KB)
- NICE Technology Appraisal TA809 - Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease (PDF 514KB)
- NICE Technology Appraisal TA819 - Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies (PDF 512KB)
- NICE Technology Appraisal TA814 - Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis (PDF 515KB)
- NICE Technology Appraisal TA815 - Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs (rapid review of TA711) (PDF 563KB)
- NICE Technology Appraisal TA817 - Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence (PDF 513KB)
- NICE Technology Appraisal TA813 - Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors (PDF 511KB)
- NICE Technology Appraisal TA818 - Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma. (PDF 510KB)
- NICE Technology Appraisal TA821 - Avalglucosidase alfa for treating Pompe disease (PDF 511KB)
- NICE Technology Appraisal TA820 - Brolucizumab for treating diabetic macular oedema (PDF 516KB)
- NICE Clinical Guideline NG220 - Multiple sclerosis in adults: management (updates and replaces CG186) (PDF 512KB)
- The Coronavirus Act 2020 (Extension of Powers to Act for the Protection of Public Health) (No. 2) Order (Northern Ireland) 2022 (PDF 517KB)